Resultados de la búsqueda 81-90 of 6871 for random glucose

  1. Oncología (médica) - Ensayos clínicos

    The purpose of this study is to compare standard glucose monitoring versus continuous glucose ... This is a multicenter, two-arm, randomized, double-blind ...

  2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients with MIBG-avid, ALK wild type (or ALK unknown) disease will be randomized to one of three arms: A) current COG recommended high-risk therapy ...

  3. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This randomized phase II trial studies how well olaparib, cediranib maleate, and standard chemotherapy work in treating patients with small cell lung cancer.

  4. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This randomized phase II trial studies how well olaparib, cediranib maleate, and standard chemotherapy work in treating patients with small cell lung cancer.

  5. Cirugía - Ensayos clínicos - Mayo Clinic

    This randomized phase II/III trial studies how well radiation therapy works when given together with cisplatin compared to docetaxel or cetuximab and docetaxel ...

  6. Oncología radioterápica - Ensayos clínicos - Mayo Clinic

    This randomized phase II/III trial studies how well radiation therapy works when given together with cisplatin compared to docetaxel or cetuximab and docetaxel ...

  7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This randomized phase II trial studies how well olaparib, cediranib maleate, and standard chemotherapy work in treating patients with small cell lung cancer.

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ... randomized to receive inotuzumab. Other aims of this study include ... Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target ...

  9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Subsequent therapy will be based upon MIBG avidity and ALK status. Patients with MIBG-avid, ALK wild type (or ALK unknown) disease will be randomized to one of ...

  10. Hematología - Ensayos clínicos - Mayo Clinic

    Patients will be randomized in a 1:1 ratio to receive either alectinib, 600 mg orally twice daily (BID), or critozinib, 250 mg orally BID. Patients will receive ...